COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01465282
Recruitment Status : Completed
First Posted : November 4, 2011
Last Update Posted : March 8, 2013
Information provided by (Responsible Party):
Creabilis SA

Brief Summary:
The purpose of this study is to evaluate the effectiveness of 3 dose strengths of CT327 ointment (0.05%, 0.1% and 0.05% w/w) compared to a placebo, when applied twice daily for up to 8 weeks, to the psoriatic plaques of patients with psoriasis vulgaris.

Condition or disease Intervention/treatment Phase
Psoriasis Vulgaris Drug: CT327 0.05% Drug: CT327 0.1% Drug: CT327 0.5% Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 160 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-controlled, Phase IIb Study to Evaluate the Efficacy, Safety and Tolerability of 0.05%, 0.1% and 0.5% w/w Topical CT327 When Applied Twice Daily in Subjects With Psoriasis Vulgaris
Study Start Date : December 2011
Actual Primary Completion Date : September 2012
Actual Study Completion Date : September 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Arm Intervention/treatment
Experimental: 0.05% (w/w) CT327 ointment
0.05% (w/w) CT327 ointment applied BID for up to 8 weeks.
Drug: CT327 0.05%
0.05% CT327 (w/w) ointment

Experimental: 0.1% (w/w) CT327 ointment
0.1% (w/w) CT327 ointment applied BID for up to 8 weeks.
Drug: CT327 0.1%
0.1% CT327 (w/w) ointment

Experimental: 0.5% (w/w) CT327 ointment
0.5% (w/w) CT327 ointment applied BID for up to 8 weeks.
Drug: CT327 0.5%
0.5% CT327 (w/w) ointment

Placebo Comparator: Placebo ointment
Placebo ointment
Drug: Placebo

Primary Outcome Measures :
  1. Efficacy of CT327 ointment (0.05%, 0.1% and 0.5% w/w) compared with placebo ointment. [ Time Frame: Week 8 ]

Secondary Outcome Measures :
  1. Local and systemic toleration [ Time Frame: 8 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and female subjects aged at least 18 years.
  • Stable psoriasis vulgaris

Exclusion Criteria:

  • Subjects with guttate, erythrodermic, exfoliative or pustular psoriasis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01465282

Layout table for location information
United States, Arkansas
Hotsprings, Arkansas, United States
United States, California
San Ramon, California, United States
United States, Michigan
Bay City, Michigan, United States
United States, Minnesota
Fridley, Minnesota, United States
United States, Ohio
South Euclid, Ohio, United States
United States, Oregon
Portland, Oregon, United States
United States, Texas
San Antonio, Texas, United States
United States, Utah
Spanish Fork, Utah, United States
United Kingdom
Birmingham, United Kingdom
Cardiff, United Kingdom
Glasgow, United Kingdom
Manchester, United Kingdom
Merseyside, United Kingdom
Sponsors and Collaborators
Creabilis SA
Layout table for additonal information
Responsible Party: Creabilis SA Identifier: NCT01465282    
Other Study ID Numbers: CT327-2003
First Posted: November 4, 2011    Key Record Dates
Last Update Posted: March 8, 2013
Last Verified: March 2013
Keywords provided by Creabilis SA:
psoriasis vulgaris
topical ointment
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases, Papulosquamous
Skin Diseases